DEEPAK PAL
@deepak.pal.4206
Indore
3+ Years of experience
SEBI Registration INH000012856INVESTOGAINER RESEARCH
Trade Ideas
749
Opinions
993
Followers
111k
Expertise
Quantitative
Growth
Technical
Index Strategies
Market Commentary
Futures & Options
Technical Analysis
Trade Facts
Total Trades
0
Missed Trades
0
Profit Trades
0
0%Accuracy
Ask me Anything
Got a question? Ask me and I will answer it. Stay curious, stay hungry!
Posts
shared an insight ⚡️ 10 hours ago
Hospital Stocks CRASH! Supreme Court Questions ON!
HOSPITAL RISK-->“Sarkari Hospital Mein Jaan Ka Risk… Private Hospital Mein Jameen-Jaydaad Ka Risk!”
erns over steep mark-ups on medicines sold through private hospitals.
Stocks including
APOLLOHOSP
, Max Healthcare, Fortis Healthcare, Yatharth Hospital, Medanta and Aster DM came under pressure, with several names falling sharply during the session.
--->What Did the Supreme Court Question?
The Supreme Court was hearing petitions related to medicine pricing, generic prescriptions and medical-device pricing under the Drugs (Prices Control) Order, 2013.
During the hearing, the bench highlighted a striking example:
A cancer medicine supplied to retailers for around ₹2,700 was cited as carrying an MRP of around ₹27,000.
The Court questioned how such a large gap could exist and also raised concerns about hospitals requiring patients to purchase medicines through their own or designated pharmacies.
---->Why Are Hospital Stocks Falling?
The market is worried about one simple issue:
Medicine mark-ups can be an important part of hospital economics.
If hospitals are eventually required to operate with significantly lower medicine margins, it could potentially affect:
• Pharmacy-related revenue
• EBITDA margins
• Profitability
• Revenue per patient
---->The 16% Rule — Don't Misunderstand It
This is where the headlines can become misleading.
The Supreme Court questioned whether a uniform 16% margin could be applied more broadly.
But:
The Court has NOT ordered a universal 16% cap on all medicines.
The existing 16% retailer-margin concept is already used in parts of India's drug-price-control framework for scheduled formulations.
---->Bottom Line
Hospital stocks are falling because the Supreme Court has put hospital medicine mark-ups and captive pharmacy practices under the regulatory spotlight.
The market is currently pricing in the risk of tighter regulation, not a confirmed 16% margin cap. shared an insight ⚡️ 18 hours ago
PRE MARKET---> DONT MISS THE TODAYs TRIGGERS, READ NOW!
PRE-MARKET REPORT | FII Selling Persists, But Crude Cools — Can Nifty Defend 22,500 and Bank Nifty Hold 54,000?
Indian markets are heading into today's session with a mixed setup.
However, there are some positives.
Crude oil has cooled sharply, Nifty and Bank Nifty recovered from their lower levels, and domestic institutional investors continued to provide strong buying support.
The key question for today:
Can lower crude and support at lower levels help Indian markets stabilize despite heavy FII selling?
---->US Markets Closed Slightly Lower
Wall Street ended Tuesday with modest declines as rising Treasury yields continued to pressure equities.
• Dow Jones: -0.30%
• S&P 500: -0.17%
• Nasdaq Composite: -0.04%
The 10-year U.S. Treasury yield remained above 5.2%, keeping global investors cautious.
--->Crude-linked stocks could therefore remain in focus today.
Stocks to watch:
IndiGo |
ASIANPAINT
| Berger Paints | MRF | Apollo Tyres
----->FII / DII Activity
Institutional Activity — ₹ Crores
Segment FII DII
Cash Market -₹9,980.22 Cr +₹6,952.71 Cr
Index Futures -₹1,167.00 Cr —
Index Options -₹39,657.18 Cr —
Stock Futures +₹5,343.83 Cr —
Stock Options +₹406.81 Cr —
🚨 FII Selling Remains the Biggest Concern
---->Nifty Took Support From Lower Levels
Key Nifty Support: 22,500
This is the major level to watch today.
If Nifty holds above 22,500, another attempt towards 22,750–22,800 cannot be ruled out.
Key Support: 54,000
If Bank Nifty manages to defend 54,000, banking stocks could see some recovery after recent weakness
--->Today's Market Setup
Positive Triggers
• Crude oil down around 2.5%
• Nifty recovered from lower levels
• Bank Nifty defending the 54,000 area
• Strong DII buying of ₹6,952 crore
• FII stock-futures buying
Risk Factors
• FII cash selling of ₹9,980 crore
• Heavy FII index-options selling
• U.S. Treasury yields remain elevated
• Global geopolitical uncertainty shared an insight ⚡️ 29th Sep
TITAN UPDATE->घड़ी सिर्फ Time दिखाती नहीं, Time बदलती भी है!
Titan is betting that India's appetite for premium mechanical and automatic watches still has plenty of room to grow.
And the numbers show why the company is paying attention.
---> Automatic Watches Could Become a ₹400 Crore Business
Titan expects its automatic-watch business to reach ₹350–400 crore this fiscal, compared with around ₹265 crore last year.
--->Why Are Mechanical Watches Making a Comeback?
In a world where smartphones tell us the exact time, people are increasingly buying watches for something else:
Craftsmanship.
Engineering.
Design.
Status
---->It tells time — but it also tells a story.
TITAN
Is Betting on Premiumisation
India's watch market is gradually moving beyond functionality.
Consumers are increasingly willing to spend on:
• Premium watches
• Automatic movements
• Mechanical craftsmanship
• Luxury designs
• Branded timepieces
This creates an opportunity for Titan to move consumers up the value chain.
---->The Interesting Part
Think about the irony:
Technology gave us smartphones that tell time for free.
Yet consumers are increasingly willing to pay thousands—or even lakhs—for a mechanical watch that does one simple thing:
Tell the time.
Because today, a premium watch isn't just about knowing what time it is.
It's about how you choose to wear time.
---->Stock in Focus
TITAN
ETHOS
TIMEX
KDDL
---> Bottom Line
Because sometimes, the most valuable thing about a watch isn't the time it shows — it's the value people attach to wearing it.FAQ's
What are the top stock recommendations by DEEPAK PAL?
DEEPAK PAL regularly shares stock views and market analysis on StockGro. Some of the stocks they have recently shared views on include Avenue Supermarts Ltd. (Bullish), APOLLOHOSP, ASIANPAINT and TITAN. Explore DEEPAK PAL's complete list of posts and trade views on their StockGro profile.
How can I follow DEEPAK PAL's latest investment insights?
You can follow DEEPAK PAL's latest investment insights, stock recommendations, and market analysis on StockGro App. Additionally, you can check their detailed stock analysis reports in the StockGro blog section.
What is DEEPAK PAL's investment strategy?
DEEPAK PAL follows a data-driven, research-backed investment strategy focused on maximizing returns while managing risk. Their approach includes fundamental and technical analysis, portfolio diversification, and sectoral trends to identify high-potential stocks.
How long has DEEPAK PAL been a SEBI-registered Research Analyst (RA)?
DEEPAK PAL has been a SEBI-registered Research Analyst and have 3+ Years of experience. With extensive experience in stock market analysis and investment research, they have guided investors in making informed and profitable decisions.
Where can I see DEEPAK PAL's past performance and stock picks?
You can check DEEPAK PAL's past stock recommendations, success rate, and investment insights on their StockGro profile. Their historical stock picks reflect a track record of strategic investment decisions based on thorough research.
How can I contact DEEPAK PAL for stock market advice?
For stock market guidance from DEEPAK PAL, you can connect through their StockGro profile. Some RAs may also provide personalized investment consultations based on their availability and SEBI regulations.
What is DEEPAK PAL's track record in predicting market movements?
DEEPAK PAL has a proven track record of accurate market analysis and trend predictions. By analyzing economic indicators, market sentiment, and technical charts, they have consistently helped investors make well-timed investment decisions.
What is the SEBI Registration number for DEEPAK PAL?
DEEPAK PAL is a SEBI-registered Research Analyst with the SEBI Registration INH000012856. This ensures that their investment recommendations comply with SEBI's regulatory framework for investor protection and financial advisory standards.
Be Financially Free with StockGro